Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab/Paclitaxel or Epirubicin/Docetaxel in Breast Cancer
NCT02307227Phase 2Completed
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- Apr 2006
- Primary completion
- Apr 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, paclitaxel, epirubicin, docetaxel in breast cancer, sponsored by Centro di Riferimento Oncologico di Aviano. Started Apr 2006; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02307227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307227.